NCT05890781 Engineering Immune Organoids to Study Pediatric Cancer
| NCT ID | NCT05890781 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Condition | Brain Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2023-05-12 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2023-05-12 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Eligibility Criteria
Inclusion Criteria: * Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied * Medical suspicion or diagnosis of one of the following diseases, regardless of stage: * Brain tumors * Renal tumors * Neuroblastoma * Sarcomas * Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Affiliated to a social security system or beneficiary of the same. Exclusion Criteria: * Any histology not mentioned in the inclusion criteria * Adult patient or parents/guardians incapable/incapable of giving its/their consent * Patients deprived of their liberty by a judicial or administrative decision
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05890781 clinical trial?
This trial is open to participants of all sexes, up to 25 Years, studying Brain Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05890781 currently recruiting?
Yes, NCT05890781 is actively recruiting participants. Contact the research team at claudia.pasqualini@gustaveroussy.fr for enrollment information.
Where is the NCT05890781 trial being conducted?
This trial is being conducted at Villejuif, France, Paris, France.
Who is sponsoring the NCT05890781 clinical trial?
NCT05890781 is sponsored by Gustave Roussy, Cancer Campus, Grand Paris. The trial plans to enroll 108 participants.